← DYAI
DYAI— DYADIC INTERNATIONAL INC
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Total revenue | $265K-86.0% | $1.9M-34.8% | $2.9M+1073.3% | $247K | $0-100.0% | $1.6M-4.7% | $1.7M+29.8% | $1.3M |
| Costs of research and development revenue | $601K-49.7% | $1.2M-39.5% | $2.0M-6.9% | $2.1M+9.2% | $1.9M+36.5% | $1.4M-2.4% | $1.5M+42.1% | $1.0M |
| Costs of grant revenue | $1.7M | — | — | — | — | — | — | — |
| Research and development | $2.2M+5.4% | $2.0M-38.0% | $3.3M-26.7% | $4.5M-46.4% | $8.4M+117.0% | $3.9M+25.3% | $3.1M+46.9% | $2.1M |
| General and administrative | $5.8M-6.1% | $6.1M+5.5% | $5.8M-9.4% | $6.4M-4.1% | $6.7M+10.1% | $6.1M+10.2% | $5.5M+22.0% | $4.5M |
| Foreign currency exchange loss | $47K+107.9% | $23K-41.3% | $38K-23.0% | $50K-48.5% | $97K+55.4% | $62K | — | — |
| Total costs and expenses | $10.3M+9.4% | $9.4M-15.6% | $11.1M-15.0% | $13.1M-23.6% | $17.1M+47.3% | $11.6M+6.1% | $11.0M+23.4% | $8.9M |
| Loss from operations | -$7.2M-21.9% | -$5.9M+28.3% | -$8.2M+19.0% | -$10.2M+31.0% | -$14.7M-46.9% | -$10.0M-8.0% | -$9.3M-22.3% | -$7.6M |
| Interest income | $284K-37.8% | $457K+9.7% | $417K+131.0% | $180K+248.9% | $52K-88.4% | $447K-54.6% | $985K+10.1% | $895K |
| Gain on sale of Alphazyme | $63K | — | $1.0M | $0 | — | — | — | — |
| Total other income (expense), net | -$172K-287.4% | $92K-93.6% | $1.4M+233.2% | $430K-74.0% | $1.7M+126.5% | $732K | — | — |
| Net loss | -$7.4M-26.8% | -$5.8M+14.5% | -$6.8M+30.2% | -$9.7M+25.5% | -$13.1M-40.2% | -$9.3M-12.2% | -$8.3M-46.0% | -$5.7M |
| Basic net loss per common share | -$0.23-15.0% | -$0.2+16.7% | -$0.24+29.4% | -$0.34+27.7% | -$0.47 | — | — | — |
| Diluted net loss per common share | -$0.23-15.0% | -$0.2 | — | — | — | — | — | — |
| Basic weighted-average common shares outstanding | $32.6M+11.3% | $29.3M+1.8% | $28.8M | — | $27.8M | — | — | — |
| Diluted weighted-average common shares outstanding | $32.6M+11.3% | $29.3M | — | — | — | — | — | — |
| Nonrelated Party [Member] | ||||||||
| Interest expense | -$124K+11.4% | -$140K | $0 | — | — | — | — | — |
| Related Party [Member] | ||||||||
| Research and Development [Member] | ||||||||
| Grant [Member] | ||||||||
| License [Member] | ||||||||
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.